

## This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Endocrine/metabolic disease</b>				
Diabetes	Gap junction protein $\delta 2$ , 36 kDa (GJD2; CX36; connexin-36)	<p>Mouse studies suggest increasing CX36 levels could help treat or prevent type 1 diabetes. CX36 is a transmembrane protein present in the junction between <math>\beta</math> cells and islet cells. In a mouse model of type 1 diabetes, higher expression of Cx36 prevented <math>\beta</math> cell apoptosis, decreased blood glucose levels and increased insulin levels compared with lower Cx36 expression. Next steps could include identifying a therapeutic approach for increasing CX36 levels.</p> <p><i>SciBX</i> 4(46); doi:10.1038/scibx.2011.1297 Published online Dec. 1, 2011</p>	Patent and licensing status unavailable	<p>Klee, P. <i>et al. J. Clin. Invest.</i>; published online Nov. 7, 2011; doi:10.1172/JCI40509  <b>Contact:</b> Paolo Meda, University of Geneva Medical School, Geneva, Switzerland                      e-mail: <a href="mailto:paolo.meda@unige.ch">paolo.meda@unige.ch</a></p>